EUVIMEDEUVIMED entdecken
Kommentar

In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y

Ellis W Lader

Annals of Internal Medicine · 2023

DOI: 10.7326/j22-0102 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Ellis W Lader. Beteiligte Einrichtung: WMCHealth Heart and Vascular Institute, Kingston, New York, United States (E.W.L.). Hauptthemen laut MEDLINE: Rheumatic Heart Disease, Atrial Fibrillation, Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOURCE CITATION: Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic Heart DiseaseAtrial FibrillationStrokeHumansRivaroxabanAnticoagulantsFactor Xa InhibitorsVitamin KTreatment Outcome

Substanzen

RivaroxabanAnticoagulantsFactor Xa InhibitorsVitamin K

Autor:innen und Institutionen

  • WMCHealth Heart and Vascular Institute, Kingston, New York, United States (E.W.L.).

Zitieren

APA

Lader, E. W. (2023). In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Annals of Internal Medicine. https://doi.org/10.7326/j22-0102

Vancouver

Lader EW. In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Annals of Internal Medicine. 2023. doi:10.7326/j22-0102

BibTeX
@article{Lader2023,
  author = {Lader, Ellis W},
  title = {In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j22-0102}
}
Kostenlos starten →